- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of February 26
The Center for Biosimilars recaps the top 5 biosimilars articles for the week of February 26, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of February 26.
Number 5: The US Patent Trial and Appeal Board has decided that the Saint Regis Mohawk Tribe cannot claim sovereign immunity from inter partes review of Allergan’s patents covering Restasis, and that the proceedings can continue with Allergan as the patent owner.
Number 4: Infliximab has been proposed as a potential combination treatment that could enhance the effects of chemotherapy in patients with colon cancer.
Number 3: The American College of Rheumatology has updated its health policy statements for 2018, and biosimilars featured heavily in the organization’s concerns for the year ahead.
Number 2: Virginia’s House and Senate have passed a new bill that prohibits pharmacy benefit managers from penalizing pharmacists for sharing drug price information with customers.
Number 1: A health economist from Harvard Medical School is warning that, if biosimilars continue their current trajectory, they could fail to deliver on their promise to provide cost savings to the US health system.
Finally, last week, our e-newsletter asked for your thoughts on whether the extrapolation of indications for biosimilars is reasonable.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Eye on Pharma: EU Aflibercept Approvals; Biosimilars Canada Campaign; Celltrion Data
November 19th 2024The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign to provide sustainable solutions to employers; Celltrion shares positive data for 2 biosimilars.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Breaking Down Biosimilar Barriers: Interchangeability
November 14th 2024Part 3 of this series for Global Biosimilars Week, penned by Dracey Poore, director of biosimilars at Cardinal Health, explores the critical topic of interchangeability, examining its role in shaping biosimilar adoption and the broader implications for accessibility.
